
Medial EarlySign
Founded Year
2013Stage
Incubator/Accelerator | AliveTotal Raised
$50MAbout Medial EarlySign
Medial EarlySign helps healthcare systems with their early detection and prevention of high-burden diseases and chronic medical conditions. The outcome-focused clinical software solutions (AlgoMarkers) find subtle, early signs of high-risk patient trajectories in existing lab results and ordinary EHR data already collected in the course of routine care. The company was founded in 2013 and is based in Israel.
Medial EarlySign's Product Videos


Medial EarlySign's Products & Differentiators
AlgoAnalyzer
EarlySign’s AlgoAnalyzer is a server-side software platform for running various healthcare calculators, including patient-specific algorithmic and predictive models called AlgoMarkers™.
Expert Collections containing Medial EarlySign
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Medial EarlySign is included in 3 Expert Collections, including Artificial Intelligence.
Artificial Intelligence
10,932 items
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Conference Exhibitors
5,302 items
Digital Health
10,565 items
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Latest Medial EarlySign News
Mar 11, 2021
Share Collaboration will Provide Healthcare Organizations an End-to-End Solution for Early Identification and Improved Care for High-Risk Populations Datos Health , a leader in remote care automation , and Medial EarlySign , an innovator in AI-based actionable clinical insights , announced a collaboration to offer state-of-the-art integrated solutions to identify high-risk patients who stand to benefit from remote care programs. The solution is focused on helping providers achieve better outcomes in vulnerable populations, as they transition to value-based care. The collaboration combines EarlySign’s predictive solutions for identifying patients at increased risk of specific chronic or life-threatening conditions with Datos’ corresponding automated remote care programs, helping to prevent or delay the onset of disease and downstream complications. The introduction of this solution is particularly crucial as high-risk population management becomes a must-have competency for healthcare providers of all denominations, with organizations striving to deliver better preventive services across the care continuum. Related Posts “The transition to value-based care and pre-emptive approaches requires deeper insight into the patient population. Medial EarlySign’s AI-based clinical approach facilitates proactive and preventative treatment through earlier identification of high-risk patient trajectories when interventions stand more chance of halting or preventing the onset of disease,” said Ori Geva , CEO and Co-Founder of Medial EarlySign. “Datos provides healthcare stakeholders new options and models of intervention for these high-risk patients, including a way to seamlessly enable more frequent, or even continuous monitoring and engagement that can reduce intervention costs and significantly improve care delivery and patient outcomes. “Datos has spent the last several years focused on building a solution for personalized and automated remote care across a diverse range of disease conditions, enabling better care and a higher level of patient engagement and participation,” said Uri Bettesh , CEO and Founder of Datos Health. “The prospect of extending automated remote care to pre-disease and early onset stages opens up a new world of possibilities for the ultimate goal of keeping people healthier for longer.”
Medial EarlySign Frequently Asked Questions (FAQ)
When was Medial EarlySign founded?
Medial EarlySign was founded in 2013.
Where is Medial EarlySign's headquarters?
Medial EarlySign's headquarters is located at Hanager 6, Hod Hasharon.
What is Medial EarlySign's latest funding round?
Medial EarlySign's latest funding round is Incubator/Accelerator.
How much did Medial EarlySign raise?
Medial EarlySign raised a total of $50M.
Who are the investors of Medial EarlySign?
Investors of Medial EarlySign include PlayBeyondBio, Horizon Ventures, aMoon Fund, Nir Kalkstein and Marius Nacht Life Sciences Fund.
Who are Medial EarlySign's competitors?
Competitors of Medial EarlySign include DataRobot and 5 more.
What products does Medial EarlySign offer?
Medial EarlySign's products include AlgoAnalyzer and 2 more.
Who are Medial EarlySign's customers?
Customers of Medial EarlySign include Geisinger Health and Northwest Permanente.
Compare Medial EarlySign to Competitors

ClosedLoop operates as a healthcare data science platform. It enables providers, payers, and value-based care organizations to make accurate, explainable, and actionable predictions of individual-level health risks, improve outcomes, and reduce costs. It was formerly known as Deep Health Technologies. The company was founded in 2017 and is based in Austin, Texas.
Epic specializes in the development of software for healthcare organizations.
Alvee provides a view of a patient's social needs with a special emphasis on health equity. It uses predictive analytics with constructed algorithms to empower payers and providers to proactively identify, act on, and track social needs for their patients and helps them to pinpoint and address racial disparities. The company was founded in 2021 and is based in Marina del Rey, California.
Life Singularity offers an AI/VR/Quantum-driven predictive health platform delivering personalized, geospatial monitoring with a strong focus on capturing Social Determinants of Health (SDOH) for predicting “prospective” virtual care for the prevention of health events.

Decode Health is a precision medicine analytics company that fuels collaboration within pharmaceutical, diagnostic, and technology companies. The company leverages its platform and expertise in genomics, clinical data, social determinants of health, and other healthcare data sources, to bring actionable insights into focus quickly. It creates data assets, products, and services that improve patient outcomes and reduce costs. Projects include genomic data creation, biomarker discovery, RNA diagnostics, and broader population health analytics. Decode Health was founded in 2019 and is headquartered in Nashville, Tennessee.

Cedar Gate Technologies is a value-based care performance management analytic and operating company. Cedar Gate provides high-performance analytic and operating systems that enable users to meet and exceed the performance thresholds of risk-based contracts and programs.